 |
|
|
| |
LONG-TERM INFLAMMATION BIOMARKER CHANGES WITH FOSTEMSAVIR IN
HEAVILY TREATMENT-EXPERIENCED ADULTS WITH HIV-1: EXPLORATORY ANALYSES OF THE PHASE 3 BRIGHTE STUDY
|
| |
| |
Andrew Clark,1 David Asmuth,2 Shiven Chabria,3 Amy Pierce,4 Peter Ackerman,3 Marcia Wang,5 Fangfang Du,5 Jerry L. Jeffrey,4 Max Lataillade3
1ViiV Healthcare, Brentford, UK; 2University of California, Davis, Sacramento, CA, USA; 3ViiV Healthcare, Branford, CT, USA; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5GlaxoSmithKline, Collegeville, PA, USA
|
| |
|
|
|
|
|
